Traditionally, treatment for chronic conditions addressed symptoms or was disease modifying and required lifelong periodic administration and recurring costs. This research extends a previous study by analyzing member retention for adult patients with certain rare diseases.
A summary of an ICER cost-effectiveness analysis published in JMCP found that despite incremental clinical benefits, biologics used to treat asthma have low long-term value for money.
A systematic review published in JMCP demonstrates that while life expectancy in HIV patients has increased, there is an increased incidence of age- and ART-associated comorbidities. This has important implications for future cost effectiveness analysis.
A systematic review published in JMCP demonstrates that while life expectancy in HIV patients has increased, there is an increased incidence of age- and ART-associated comorbidities. This has important implications for future cost effectiveness analysis.
This JMCP study compares pay-for-success and pay-for-failure models to identify the short- and long-term incentives for each that manufacturers and payers should consider when developing value-based contracts. More research is needed on the effect of different types of value-based contract schemes on cost and clinical outcomes.
This JMCP study compares pay-for-success and pay-for-failure models to identify the short- and long-term incentives for each that manufacturer and payer should when developing value-based contracts. More research is needed on the effect of different types of value-based contract schemes on cost and clinical outcome.